RELMADA THERAPEUTICS, INC. Revenue
RELMADA THERAPEUTICS, INC. (RLMD) reported Revenue of $682 for the 3-month period ending 2014-02-28, per its 10-Q filed 2014-04-15.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2014-04-15
- RELMADA THERAPEUTICS, INC. revenues for the quarter ending 2014-02-28 was $682.00, a 70.93% decline year-over-year.
- RELMADA THERAPEUTICS, INC. revenues for the quarter ending 2013-11-30 was $1.85K, a 13.91% decline year-over-year.
- RELMADA THERAPEUTICS, INC. revenues for the quarter ending 2013-08-31 was $0.00, a 100.00% decline year-over-year.
- RELMADA THERAPEUTICS, INC. revenues for the quarter ending 2013-05-31 was $634.00, a 58.50% increase year-over-year.
- RELMADA THERAPEUTICS, INC. revenues for fiscal 2013 was $5.13K, a 35.41% decline from fiscal 2012.
- RELMADA THERAPEUTICS, INC. revenues for fiscal 2012 was $7.94K.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month | Revenues 21 month | Revenues 24 month | Revenues 27 month | Revenues 30 month | Revenues 33 month |
|---|---|---|---|---|---|---|---|---|---|
| 2014-02-28 | $682.00 10-Q · filed 2014-04-15 | $2.53K 10-Q · filed 2014-04-15 | $2.53K derived: sum of 3 quarters · filed 2014-04-15 | $3.17K derived: sum of 4 quarters · filed 2014-04-15 | $15.60K 10-Q · filed 2014-04-15 | ||||
| 2013-11-30 | $1.85K 10-Q · filed 2014-01-13 | $1.85K derived: sum of 2 quarters · filed 2014-01-13 | $2.48K derived: sum of 3 quarters · filed 2014-01-13 | $4.83K derived: sum of 4 quarters · filed 2014-04-15 | $14.92K 10-Q · filed 2014-01-13 | ||||
| 2013-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-16 | $634.00 derived: sum of 2 quarters · filed 2013-12-16 | $2.98K derived: sum of 3 quarters · filed 2014-04-15 | $5.13K 10-K · filed 2013-12-16 | $13.07K 10-K · filed 2013-12-16 | ||||
| 2013-05-31 | $634.00 10-Q · filed 2013-07-12 | $2.98K derived: sum of 2 quarters · filed 2014-04-15 | $5.13K 10-Q · filed 2013-07-12 | $6.64K derived: sum of 4 quarters · filed 2014-04-15 | $13.07K 10-Q · filed 2013-07-12 | ||||
| 2013-02-28 | $2.35K 10-Q · filed 2014-04-15 | $4.50K 10-Q · filed 2014-04-15 | $6.01K derived: sum of 3 quarters · filed 2014-04-15 | $6.41K derived: sum of 4 quarters · filed 2014-04-15 | $12.44K 10-Q · filed 2013-05-03 | ||||
| 2012-11-30 | $2.15K 10-Q · filed 2014-01-13 | $3.66K derived: sum of 2 quarters · filed 2014-01-13 | $4.06K derived: sum of 3 quarters · filed 2014-01-13 | $10.09K derived: sum of 4 quarters · filed 2014-01-13 | |||||
| 2012-08-31 | $1.51K derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-16 | $1.92K derived: sum of 2 quarters · filed 2013-12-16 | $7.94K derived: sum of 3 quarters · filed 2013-12-16 | $7.94K 10-K · filed 2013-12-16 | |||||
| 2012-05-31 | $400.00 10-Q · filed 2013-07-12 | $6.43K derived: sum of 2 quarters · filed 2013-07-12 | $6.43K 10-Q · filed 2013-07-12 | ||||||
| 2012-02-29 | $6.03K 10-Q · filed 2013-05-03 | $6.03K 10-Q · filed 2013-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |